Physician profile
Grace Smith
NPI 1982311122
$1,142.39
in general payments reported to CMS, 2019-2025
11 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $506 · 2024: $330 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $245.94 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $237.21 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $207.67 | 2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $204.68 | 2023-2025 | Spravato |
| Abbvie INC. | $84.89 | 2023 | |
| Tris Pharma INC | $49.81 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $31.69 | 2025 | Trintellix |
| Alkermes, INC. | $24.21 | 2023 | Aristada, Lybalvi |
| Boston Scientific Corporation | $23.31 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.86 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $15.12 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.